Licensing Technologies

Efficient commercialization for optimal impact
Hadasit is recognized across the globe for the successful licensing of biomedical technologies developed at the Hadassah University Medical Center. Hadasit boasts a rich portfolio of over 250 active patent families, covering a wide variety of novel therapeutics, diagnostics, and medical devices.

Patents

Out licensing

Spinoffs

Collaborations

Success stories

The drugs, medical devices, and cutting-edge technologies developed by Hadasit companies are preventing disease and saving lives. From blockbuster medications like Doxil to the insulin absorption device InsuPad®, Hadasist is taking innovation from the lab to the marketplace.
Doxil

Doxil is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. Developed by Prof. Yechezkal Barenholz of the Hebrew University and Prof. Alberto Gabizon of Hadassah Medical Center.

PerioChip

PerioChip is an effective, non-antibiotic adjunct treatment to scaling and root planning to reduce pocket depth in patients with adult periodontitis. PerioChip is a prescription medicine, generally well-tolerated and typically takes just one minute to insert into the periodontal pocket following SRP. Developed by Prof. Michael Friedman and Prof. Doron Steinberg of the Hebrew University and Prof. Aubrey Soskolne of Hadassah Medical Center.

Travelan

Travelan is a natural dietary supplement specifically designed to reduce the risk of infection by E. coli (ETEC) as well as Shigella, Salmonella and other bacteria that cause travelers’ diarrhea. The active ingredient in Travelan is hyperimmune bovine colostrum enriched with anti-E. coli antibodies. These antibodies bind to E. coli in the gastrointestinal tract, preventing them from attaching to the intestinal wall and thereby neutralizing their ability to cause diarrhea and its associated symptoms. Developed in collaboration with Prof. Yaron Ilan of Hadassah Medical Center.

Granagard

GranaGard is a submicron self-emulsion formulation of pomegranate seed oil (PSO). PSO contains high concentrations of Punicic Acid (PA), among the strongest natural antioxidants. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease which presents neurodegenerative features reminiscence of Alzheimer’s disease and to reduce disease burden in a mouse model of Multiple Sclerosis. Developed by Prof. Ruth Gabizon of Hadassah Medical Center and Prof. Shlomo Magdassi of the Hebrew University.

Insupad

InsuPad® enables patients on intensive insulin therapy to take control of their disease and reach treatment targets in more efficient way. By gently warming the skin, it increases blood flow, helping the body absorb insulin better and faster. The result is lower insulin dosage, less hypo, and more freedom. Developed in collaboration with Prof. Itamar Raz of Hadassah Medical Center.

Lubo Collar

The Lubo Collar lets patients breathe to live another day by offering a combined solution for both airway and immobilization needs. It is the only non-invasive solution that can safely open the airway by imitating the jaw thrust maneuver for a long time. The Lubo is the only immobilization device that allows the caregiver to manage the airway easily and frees the neck from the “traditional neck grasp” while performing solid immobilization. Developed by Dr. Omri Lubovsky of Hadassah Medical Center and Dr. Michal Lubovsky of Tel Aviv University.

Fidmi Medical

Fidmi is the new low-profile gastrostomy system (PEG device) for initial placement that stays in place, eliminates the need for frequent replacements, and reduces clogging. Fidmi has received 510k clearance from the FDA and started its commercialization in the U.S. in 2020 with the US distributor Micro-Tech Endoscopy.

Infinix

Infinix™ line of advanced dental restoratives, based on the nano-polymer additive that protects against microbial infection which transforms regular implantable and non-implantable devices to biofilm-resistant platforms.

Guide In Medical

Novel groundbreaking non-invasive guided intubation device, that enables clear identification of the trachea, as well as fast, accurate and safe intubations even in the most difficult clinical scenarios in which visualization of the trachea is very limited. The product is ISO 13485 certified and received the CE Mark and the FDA market approval.

Germs Over

The Hadassah Medical Organization, the Israel Institute for Biological Research (IIBR) and Tera Novel, an Israeli start-up company, have collaboratively developed an innovative antiviral and antibacterial mask, which contains a disinfectant that has been proven to be 99.99 percent effective in killing the coronavirus. This patented technology has been approved by the Israel Ministry of Health for public marketing and use.

Portfolio

CellCure

Cell Cure Neurosciences Ltd., a subsidiary of BioTime, Inc., is a biotechnology company focused on developing cell therapies for retinal and neural degenerative diseases. Cell Cure technology is based on human embryonic stem cells (hESC), which, for the first time in the history of medicine, open the door to industrial-scale manufacture of any cell type in the human body. Cell Cure is using these powerful stem cells to manufacture a particular cell type in the retina called the Retinal Pigment Epithelial (RPE) cell.

Granalix

Granalix Ltd. generates innovative formulations of natural compounds that increase their bioavailability and allow them to target organs of interest and, in particular, the brain. The company’s first product – GranaGard – is a submicron self-emulsion formulation of pomegranate seed oil (PSO). PSO contains high concentrations of Punicic Acid (PA), among the strongest natural antioxidants. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease which presents neurodegenerative features reminiscent of Alzheimer’s disease and to reduce disease burden in a mouse model of Multiple Sclerosis.

KAHR

KAHR Medical Ltd. (“KAHR”) is an immuno-oncology drug development company whose mission is to develop novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. KAHR’s drug development pipeline is built around the Dual Signaling Proteins (DSP) technology which harnesses the power of the TNF Superfamily (regulators of the immune system) for treatment of disease. KAHR actively operates two drug-development programs, KAHR-101 and KAHR-102, representing proof-of-concept for its two proprietary platforms.

Moebius Medical

Moebius Medical Ltd. is a clinical stage biotechnology company which is developing a novel and sustainable pain relief treatment for osteoarthritis. The company’s lead product for osteoarthritis of the knee, MM-II, leverages the physical properties of proprietary liposomes to lubricate the joint and reduce friction and wear, thus leading to joint pain reduction.

GHF

GHF – Golden Heart Flower Ltd. was established to support people with glycogen storage diseases with limited treatment options. The company is developing a portfolio of oral medicines that target underlying disease pathogenesis. Based on the lead compound’s mechanism of action, larger commercial opportunities are being pursued. GHF was established by an entrepreneur who wanted to find a cure for his mother’s disease, and acquired the license from Or Kakhlon’s Laboratory of Experimental Neurology at Hadassah, in collaboration with Prof. Miguel Weil from Tel-Aviv University. Prof. Alexander Lossos opened the first clinical site at Hadassah Hospital.

Guide In Medical

Novel groundbreaking non-invasive guided intubation device, that enables clear identification of the trachea, as well as fast, accurate and safe intubations even in the most difficult clinical scenarios in which visualization of the trachea is very limited. The product is ISO 13485 certified and received the CE Mark and the FDA market approval.

Immuron

Immuron Ltd. is a publicly-listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally-stable therapeutic as a potential oral targeted therapy for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in their pathogenesis.

Akashi Therapeutics

Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Founded by leading patient organizations and biotechnology industry veterans, Akashi is managed by a seasoned team of drug development experts. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a fatal, aggressive muscle-wasting disease to a chronic, manageable condition.

Insuline Medical

Insuline Medical is a publicly-listed Israeli medical device company (INSL.TA). They developed a device that enables patients on intensive insulin therapy to take control of their disease and reach treatment targets in a more effective way. Insuline Medical has been active in developing a new approach to insulin therapy care since 2007, and has developed two medical devices using similar technology. InsuPatch & InsuPad are both designed to improve the current meal-time insulin therapy.

Exosomm

Inspired by the virtues of breast milk and its unique health properties, EXOSOMM is developing an exciting step towards care and quality of life for patients suffering from inflammatory bowel diseases (IBD). The company is backed by Prof. Shimon Reif, Head of the Department of Pediatrics at Hadassah, Dr. Regina Golan-Gerstl, Director of the Hadassah Pediatric Laboratory, and Dr.Yaffa Elbaum-Shiff, Deputy Director of the Department of Nutrition at Tel Aviv Medical Center, and led by CEO Netta Granot. Exosomm harnesses the natural properties of milk-derived nano-molecules found naturally in mammalian milk by creating a portfolio of exosomes-based nutritional solutions. The company was established in partnership with the Galil-Ofek incubator.

Sakura BIO

In October 2022 Hadasit in partnership with VLX Ventures has spun off a new cell therapy company called Sakura Bio. The company arises from the proprietary technology invented by Prof. Amnon Peled, Head of the Hadassah Gene Therapy Institute, and shall focus on developing SAK (super activated killer T cells). This is an off the shelf, allogenic T-cell therapy produced via a simple, relatively shot manipulation of naïve PBMC, applicable to a variety of cancers and particularly effective in acute myeloid leukemia (AML).

ImmunyX

Immunyx is a drug development company focused on modulating neutrophil function to treat disease. Numerous high burden illnesses such as COPD, cancer, and arthritis involve deregulated neutrophils which exacerbate, and sometimes cause, the underlying pathology. Using its platform technology to specifically manipulate neutrophils using a targeted nanoparticle, Immunyx will bring new therapies to several diseases where neutrophil treatment could advance a cure. Currently there are no FDA approved drugs targeting neutrophil activity in disease, providing Immunyx the potential to provide first in class therapies for a variety of diseases. Immunyx was established in collaboration with VLX incubator, based on the development of Prof. Zvi Friedlander, Director of the Department of Internal Medicine and Corona at Hadassah Ein Kerem, Prof. Zvika Granot and Dr. Seth Salpeter from the Hebrew University.

BrainWatch Tech

BrainWatch Tech, established by the alumnies of the Jerusalem BioDesign program, is developing a real-time, continuous, automatic pupil reflex monitoring system. Our Solution is intended for assessing the neurological status of unconscious patients in cases of traumatic brain injury, stroke, and brain surgery.

NeuroGenesis

NeuroGenesis is a clinical stage cellular therapy company focusing on a proprietary subpopulation of bone marrow stem cells that are selected and enhanced to become remyelinating & regenerative biofactory cells. The platform NG CELL™️ technology is optimized to treat central nervous system diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

Fidmi Medical

Fidmi is the new low-profile gastrostomy system (PEG device) for initial placement that stays in place, eliminates the need for frequent replacements, and reduces clogging. Fidmi has received 510k clearance from the FDA and started its commercialization in the U.S. in 2020 with the US distributor Micro-Tech Endoscopy.

CardioVia

CardioVia provides the physicians with a minimally invasive access capability to the heart through the pericardium in order to treat the most prevalent Cardiovascular Diseases and arrhythmias without using a needle. ​By using cutting edge technologies with the simplest ideas CardioVia will facilitate performance of surgeries on the outer surface of the heart like never seen before.

Dio Tree

Dio Tree is developing first-in-class small molecule for the treatment of ovarian cancer. The technology is based on inhibition of the enzyme DIO3, a major driver in many types of cancer, specifically, ovarian cancer. The molecule was developed by: Prof. Bernard Lerer, Founder of Hadassah’s Biological Psychiatry Laboratory and Hadassah BrainLabs;Dr. Tzuri Lifschytz of the Biological Psychiatry Laboratory; and Prof. Govindasamy Mugesh from the National Institute of Science in India. Prof. Lerer joined forces with Prof. Osnat Ashur-Fabian, Director of the Laboratory for Applied Oncology Research at the Hematology Institute at Meir Hospital, who led the preclinical study. This unique collaboration led to the establishment of DioTree.

Contact
Hadasit

Jerusalem BioPark, Hadassah Ein Kerem POB 12000, Jerusalem 91120, Israel
Tel. +972-2-6778757 Fax. +972-2-6437712 Email. infohadasit@hadassah.org.il